Arterial thrombosis refers to the result of sequential events involving platelet adhesion, activation, and subsequent aggregation, leading to vascular occlusion. Often, arterial thrombosis is responsible for a significant percentage of strokes and peripheral vascular diseases. According to Thrombosis UK, more than 25% of male deaths are due to heart attacks, and about 12% are due to stroke. In western countries, strokes are among the major causes of disability.
The pharmaceutical industry has made inroads into the development of drugs, over several years, for the treatment of thrombotic complications. Some of the well-established current therapeutic strategies for treatment involve targeting unstimulated platelets, discoid platelets, stimulated platelets, and aggregated platelets. Companies are advancing into different types of antithrombotic drug classes, including thrombin inhibitors and primary platelet antagonists or inhibitors.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials, across major regions of the world are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence